ALPMY
Astellas Pharma Inc.
Set alert
16.16 USD +0.16 +1.00%
16.13 Day range 16.19
10.05 52-week range 17.35
- YTD
- +21.60%
- 1 year
- +48.26%
- Open
- 16.18
- Prev close
- 16.00
- Mkt cap
- 28.98B
- Vol
- 6.47K
- Avg vol
- 100.28K
- EPS
- 1.33
- P/E
- 12.15
More statistics
- Low
- 16.13
- High
- 16.19
- Earnings
- Oct 29, 2026
Next earnings
Oct 29, 2026
Expected Oct 29, 2026. Consensus EPS estimate 0.3912.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Oct 29, 2026 | Sep 30, 2026 | 0.3912 | — | — | — |
| Aug 5, 2026 | Jun 30, 2026 | 0.3363 | 0.503 | +0.17 | +49.57% |
| Apr 27, 2026 | Mar 31, 2026 | 0.1941 | 0.1521 | -0.04 | -21.64% |
| Feb 4, 2026 | Dec 31, 2025 | 0.2916 | 0.364 | +0.07 | +24.83% |
| Oct 30, 2025 | Sep 30, 2025 | 0.1993 | 0.30 | +0.10 | +50.53% |
| Jul 30, 2025 | Jun 30, 2025 | 0.1356 | 0.40 | +0.26 | +194.99% |
News
- Is Elevance Health, Inc. (ELV) Outperforming Other Medical Stocks This Year?
- Bristol Myers Squibb (NYSE:BMY) & Astellas Pharma (OTCMKTS:ALPMY) Financial Analysis
- Astellas Pharma (OTCMKTS:ALPMY) Shares Gap Down – Here’s What Happened
- Astellas Pharma Inc. (OTCMKTS:ALPMY) Stock Short Interest Rises 519.9%
- Merck Advances European Regulatory Approval For Keytruda Combination In Bladder Cancer
- Trump's MFN Push Goes Beyond Big Pharma, Adds 9 Mid-Sized Drugmakers
- Kyowa Kirin (OTCMKTS:KYKOF) and Astellas Pharma (OTCMKTS:ALPMY) Head to Head Analysis
- New Strong Sell Stocks for August 19th
- Impax International Sustainable Economy Fund Q2 2026 Contributors And Detractors
- New Strong Sell Stocks for August 6th
Your note
Sign in to keep a note on ALPMY — it syncs with the Stock Master app.